Search Results

Sun Nuclear, a Mirion Medical company, will feature new and enhanced solutions for better Quality Management at the ESTRO Annual Meeting, May 3-6, in Glasgow, Scotland.

Sun Pharmaceutical Industries Limited today announced the successful completion of the merger of Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) with its subsidiary.

Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd. announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro shareholders at an Extraordinary General Meeting and an Ordinary Class Meeting on May 22, 2024.

Sun Nuclear, a wholly-owned subsidiary of Mirion Technologies, Inc., announced that it has designated Scripps Health as a Patient Safety Center of Excellence.

Terns Pharmaceuticals, Inc. announced the appointment of Melita Sun Jung as chief business officer, effective April 22, 2024.

Sun Nuclear today announced that it is developing new Quality Management solutions, in collaboration with Accuray, for the company’s Radixact® System with Synchrony®, which enables real-time, personalized adaptive radiation therapy. Initial innovations from the collaboration will be featured in the Sun Nuclear booth (980) at the ASTRO Annual Meeting.

Sun Pharmaceutical Industries Limited announced results from a Phase 1, multiple ascending-dose study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of GL0034 in obese adults.

Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd. announced that they have entered into a definitive merger agreement in which Sun Pharma, Taro’s controlling shareholder, has agreed to acquire all of the outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates for US$43.00 per share in cash without interest.